| __timestamp | BioCryst Pharmaceuticals, Inc. | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 9335772 |
| Thursday, January 1, 2015 | 13047000 | 12390000 |
| Friday, January 1, 2016 | 11253000 | 25602000 |
| Sunday, January 1, 2017 | 13933000 | 21262000 |
| Monday, January 1, 2018 | 29514000 | 28430000 |
| Tuesday, January 1, 2019 | 37121000 | 40849000 |
| Wednesday, January 1, 2020 | 67929000 | 60210000 |
| Friday, January 1, 2021 | 118818000 | 83664000 |
| Saturday, January 1, 2022 | 159371000 | 104097000 |
| Sunday, January 1, 2023 | 213894000 | 106916000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Iovance Biotherapeutics, Inc. and BioCryst Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, BioCryst Pharmaceuticals saw a staggering 2,765% increase in SG&A expenses, peaking at over $213 million in 2023. Meanwhile, Iovance Biotherapeutics experienced a 1,045% rise, reaching approximately $107 million in the same year.
BioCryst's expenses consistently outpaced Iovance's, particularly from 2020 onwards, where their SG&A costs nearly doubled each year. This trend highlights BioCryst's aggressive expansion and investment in administrative capabilities. Conversely, Iovance's steadier growth suggests a more measured approach. Understanding these financial strategies provides valuable insights into each company's operational priorities and market positioning.
Pfizer Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and BioCryst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Who Optimizes SG&A Costs Better? Grifols, S.A. or Iovance Biotherapeutics, Inc.
Verona Pharma plc vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing ADMA Biologics, Inc. and BioCryst Pharmaceuticals, Inc.
Bausch Health Companies Inc. vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Bausch Health Companies Inc. and BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Amicus Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Mesoblast Limited and BioCryst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared